Copper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand.
Copper(I) coordinating ligands in the Alzheimer's disease context have remained unexplored, despite the biological relevance of this redox state of the copper ion. Here, we show that the PTA ligand can remove copper from Aβ, prevent reactive oxygen species production and oligomer formation, two deleterious events in the disease's etiology.
CNRS, LCC (Laboratoire de Chimie de Coordination), 205, route de Narbonne et Université de Toulouse, F-31077 Toulouse, France. christelle.hureau@lcc-toulouse.fr.
E
E
Atrián-Blasco
E
E
Cerrada
A
A
Conte-Daban
D
D
Testemale
P
P
Faller
M
M
Laguna
C
C
Hureau
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism*; D003300:Copper / Q000302:isolation & purification* / Q000378:metabolism; D006801:Humans; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000378:metabolism
C501763:1,3,5-triaza-7-phosphaadamantane; D016229:Amyloid beta-Peptides; D009943:Organophosphorus Compounds; D017382:Reactive Oxygen Species; D003300:Copper; D000218:Adamantane